NDAORALSUSPENSION
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
anti-inflammatory and immunosuppressive effects. The precise mechanism by which vamorolone exerts its effect in patients with DMD is unknown.
Clinical Trials (1)
Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
Started Sep 2024
Loss of Exclusivity
LOE Date
Jul 16, 2040
174 months away
Patent Expiry
Jul 16, 2040
Exclusivity Expiry
Oct 26, 2030